(secondQuint)The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - PARTNER II - High Risk and Nested Registry 7.

 This is a prospective, non-randomized, multi-center trial for patients undergoing aortic valve replacement with the Edwards SAPIEN 3 THV for severe aortic stenosis.

 Patient cohorts will include those inoperable and those considered as a high surgical risk (STS 8%).

 Data will be collected from all patients for up to ten years following the valve replacement procedure.

.

 The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - PARTNER II - High Risk and Nested Registry 7@highlight

The purpose of this trial is to determine the safety and effectiveness of the Edwards SAPIEN 3 transcatheter heart valve and delivery systems which are intended for use in patients with symptomatic, calcific, severe aortic stenosis, and are in high risk.

